IRB

IRB
Name	Institutional Review Board
Caption	Institutional review process
Formation	20th century
Type	Research ethics committee
Region served	Global
Leader title	Chair

IRB

An Institutional Review Board oversees the ethical review of research involving human participants, balancing participant welfare, scientific validity, and regulatory compliance. It evaluates protocols from biomedical, behavioral, social, and clinical investigators to protect rights and safety while enabling ethically sound inquiry. IRBs operate within national statutes, international declarations, and institutional policies to review risks, consent, and data safeguards.

Overview

An IRB assesses proposals from investigators such as Anthony Fauci, Ezekiel Emanuel, Paul Farmer, Sanjay Gupta, and Janet Woodcock and interfaces with institutions like National Institutes of Health, World Health Organization, Centers for Disease Control and Prevention, European Medicines Agency, and Food and Drug Administration. It implements standards derived from documents including the Belmont Report, Declaration of Helsinki, Nuremberg Code, Council for International Organizations of Medical Sciences, and Common Rule while liaising with review bodies like ClinicalTrials.gov, Institutional Biosafety Committee, Data Safety Monitoring Board, World Medical Association, and National Bioethics Advisory Commission. Typical stakeholders include sponsors such as Pfizer, GlaxoSmithKline, AstraZeneca, Johnson & Johnson, and academic centers like Harvard University, Johns Hopkins University, University of Oxford, Stanford University, and Massachusetts Institute of Technology.

History

The review of human research evolved after episodes involving Nazi Germany, the Tuskegee syphilis study, and experiments related to Unit 731. Landmark texts and inquiries—Nuremberg Trials, the Belmont Report, and reports by the Advisory Committee on Human Radiation Experiments—prompted formalization. Regulatory milestones involved agencies including Department of Health and Human Services, Food and Drug Administration, European Commission, Health Canada, and Australian Therapeutic Goods Administration. Institutional development occurred alongside academic medicine at centers like Mayo Clinic, Cleveland Clinic, University College London, Karolinska Institute, and Peking University.

Structure and Membership

An IRB typically includes clinicians, scientists, ethicists, and community representatives drawn from institutions such as Brigham and Women's Hospital, Beth Israel Deaconess Medical Center, Mount Sinai Health System, UCSF Medical Center, and Mass General Brigham. Membership may involve lawyers, statisticians, and cultural experts affiliated with organizations like American Medical Association, American Psychological Association, Association of American Medical Colleges, National Academy of Medicine, and Royal Society. Chairs and members often have prior roles at institutions such as Columbia University, Yale University, University of Chicago, King's College London, and Imperial College London. Conflict-of-interest policies reference guidance from Office for Human Research Protections, European Commission Directorate-General for Health and Food Safety, and International Council for Harmonisation.

Functions and Responsibilities

Key responsibilities include risk–benefit assessment, informed consent review, ongoing monitoring, and determinations of exempt, expedited, or full board review for protocols submitted by investigators from centers like Dana-Farber Cancer Institute, Salk Institute, Broad Institute, Fred Hutchinson Cancer Center, and Scripps Research. IRBs review investigator brochures from sponsors such as Merck, Bristol-Myers Squibb, Novartis, Eli Lilly and Company, and Roche and assess safety reports from trial sites including Mayo Clinic, Johns Hopkins Hospital, Guy's and St Thomas' NHS Foundation Trust, Karolinska University Hospital, and Singapore General Hospital. They also ensure participant privacy protections consistent with statutes such as Health Insurance Portability and Accountability Act and directives from European Data Protection Board.

Ethical and Legal Framework

Ethical frameworks derive from canonical documents like the Declaration of Helsinki, the Belmont Report, and the Nuremberg Code while statutory obligations flow from laws and regulations including the Common Rule, Food, Drug, and Cosmetic Act, Health Insurance Portability and Accountability Act, European Union Clinical Trials Regulation, and national legislation in jurisdictions such as Canada, United Kingdom, Australia, India, and Japan. Guidance and audits come from agencies and bodies like Office for Human Research Protections, European Medicines Agency, World Health Organization, National Institutes of Health, and Council of Europe.

Review Processes and Procedures

Review pathways include exempt review, expedited review, and convened full-board review for protocols from clinical teams at institutions such as Cleveland Clinic, Vanderbilt University Medical Center, University of Pennsylvania Health System, Tokyo Medical University, and Seoul National University Hospital. Procedures involve initial administrative screening, scientific and ethical assessment, consent document evaluation, safety monitoring plans, and continuing review schedules guided by templates used by ClinicalTrials.gov, NIH, FDA, EMA, and institutional policy manuals from Princeton University, Cornell University, Duke University, University of Melbourne, and McGill University. Adverse event reporting, protocol amendments, and investigator noncompliance investigations follow processes aligned with Data and Safety Monitoring Board recommendations.

Criticisms and Controversies

Critiques have focused on perceived bureaucratic delays affecting investigators at Oxford University, Cambridge University, Harvard Medical School, Stanford Medicine, and Yale School of Medicine, conflicts of interest involving industry partnerships with Pfizer and Roche, and variable standards across jurisdictions such as United States, European Union, China, India, and Brazil. High-profile debates have involved cases linked to Tuskegee syphilis study, controversies in psychiatric research at Rockland Psychiatric Center, stem cell trials associated with Salk Institute controversies, and data sharing disputes involving 23andMe and academic consortia. Proposed reforms cite recommendations from National Academy of Medicine, World Health Organization, and Global Summit on Clinical Trials.

Category:Research ethics committees